Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with D
Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
---|---|---|---|---|---|---|---|
Q2 2022 | DIBUTYL SEBACATE | ORAL | CAPSULE | 20mg | Correction | ||
Q3 2022 | DIBUTYL SEBACATE | ORAL | CAPSULE | 15mg | Correction | ||
Q3 2022 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, COATED PARTICLES | 0.80 mg | Deletion | ||
Q3 2022 | D&C RED NO. 33 | ORAL | CAPSULE, DELAYED RELEASE | NA | Deletion | ||
Q3 2022 | DIETHYL PHTHALATE | ORAL | CAPSULE, DELAYED RELEASE PELLETS | 8.89 mg | 9mg | Deletion | |
Q3 2022 | DYE FDC BLUE NO. 40 HT LAKE | ORAL | CAPSULE | 0.16 mg | Deletion | ||
Q3 2022 | DYE FDC BLUE NO. 40 HT LAKE | ORAL | TABLET | 0.23 mg | Deletion | ||
Q3 2022 | DEXTRIN | ORAL | SOLUTION | 20.00 mg/ 5.00 ml | 480mg | Deletion | |
Q2 2022 | D&C RED NO. 27 | ORAL | TABLET, DELAYED RELEASE | 0.70 mg | MDE Replacement | ||
Q3 2022 | D&C RED NO. 27 | ORAL | TABLET, DELAYED RELEASE | 1mg | MDE Replacement | ||
Q2 2022 | DEXTROSE MONOHYDRATE | NASAL | SPRAY, METERED | 5.00 mg | MDE Replacement | ||
Q3 2022 | DEXTROSE MONOHYDRATE | NASAL | SPRAY, METERED | 20mg | MDE Replacement | ||
Q2 2022 | DIACETYLATED MONOGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 2.37 mg | MDE Replacement | ||
Q3 2022 | DIACETYLATED MONOGLYCERIDES | ORAL | CAPSULE, EXTENDED RELEASE | 8mg | MDE Replacement | ||
Q2 2022 | DIBASIC POTASSIUM PHOSPHATE | ORAL | SUSPENSION | 1.00 mg/ 1.00 ml | MDE Replacement | ||
Q3 2022 | DIBASIC POTASSIUM PHOSPHATE | ORAL | SUSPENSION | 24mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | SUSPENSION | 85.00 mg/ 5.00 ml | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | SUSPENSION | 255mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | TABLET, DELAYED RELEASE | 2.16 mg | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | ORAL | TABLET, DELAYED RELEASE | 4mg | MDE Replacement | ||
Q2 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | TRANSDERMAL | SYSTEM | 18.00 mg | MDE Replacement | ||
Q3 2022 | DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER | TRANSDERMAL | SYSTEM | 18mg | MDE Replacement | ||
Q2 2022 | DYE ORANGE PB-2148 | ORAL | TABLET | 0.16 mg | MDE Replacement | ||
Q3 2022 | DYE ORANGE PB-2148 | ORAL | TABLET | 1mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022